Assess whether scientific advice should be sought before the next trial

Situation

Pharmacovigilance medical reviewer owns scientific advice should be inside a mid-size sponsor after a complete response letter with inspection-readiness findings at a CMO as the only packet. An FAERS cluster in a demographic the trials under-enrolled is what changed the clock for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Inspection-readiness findings at a CMO reads as Proceed under protocol once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• Inspection-readiness findings at a CMO is closer to Pause the pathway after an FAERS cluster in a demographic the trials under-enrolled; Proceed under protocol would over-claim this CMC and Development Pathways extract.
• Escalate safety review is still live in inspection-readiness findings at a CMO for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.
• Inspection-readiness findings at a CMO is missing the fact pharmacovigilance medical reviewer needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether inspection-readiness findings at a CMO supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move scientific advice should be for pharmacovigilance medical reviewer.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.